Colorectal Cancer Targeted with Mass-Produced iPSC-Derived Allogeneic T Cells

Phase 1positiveiPSC-derived allogeneic γδT cellsPositive

AI Analysis

Summary

Researchers developed mass-producible iPSC-derived allogeneic γδT cells that demonstrated tumor growth suppression in preclinical mouse models of colorectal cancer, highlighting potential as a novel off-the-shelf immunotherapy.

Clinical Trial Data

Phase

Preclinical

Primary Endpoint

Met

Outcome Details

Preclinical study in mouse colorectal cancer xenograft models showed suppressed tumor growth

Importance:3/10

Sentiment:

0.60

iPSCcell therapyimmunotherapyallogeneicgamma-delta T cellscolorectal cancerpreclinical

Related Companies

$TRAX

Read the original article

Published by GEN - Genetic Engineering & Biotech News on July 24, 2026 5:24 PM

Read Original